ArticleBioresources and bioprocessing2026
Elucidating the beneficial effects of gut microbiota-derived metabolites in treating hepatocellular carcinoma: an integrated network pharmacology, molecular docking, and single-cell sequencing analysis.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third leading cause of cancer-related mortality worldwide. While accumulating evidence has highlighted the beneficial effects of gut microbiota (GM)-derived metabolites in HCC treatment, the underlying mechanisms remain unclear. We retrieved GM-derived metabolites from gutMGene v2.0, acquired their targets using the Similarity Ensemble Approach (SEA) and Swiss Target Prediction (STP), and identified HCC-related targets from public databases. Overlapping targets were then obtained via Venn diagram analysis. We constructed protein-protein interaction (PPI) networks, analyzed signaling pathways, and established a comprehensive microbiota-metabolite-target-disease (M-M-T-D) network. We also examined the correlation between core gene expression and overall survival in HCC patients using UALCAN and GEPIA2. Single-cell transcriptomic data from TISCH2 were analyzed to explore the cellular distribution of core genes. To identify candidate compounds, we evaluated the ADMET properties of metabolites and determined the compound with the highest binding affinity via molecular docking. Ultimately, 8 core targets (AKT1, IL6, PPARG, IL1B, JUN, NFKB1, CASP3, and PTGS2) were identified. These targets interacted with seven core metabolites (10-oxo-12(Z)-octadecenoic acid, genipin, 3-indolepropionic acid, succinate, acetate, propionate, and butyrate) through the M-M-T-D network to exert inhibitory effects on HCC. Single-cell RNA sequencing (scRNA-seq) analysis revealed that core gene expression was correlated with the tumor microenvironment (TME) of HCC. Molecular docking confirmed that 3-indolepropionic acid exhibited the strongest binding affinity to the core targets. Collectively, GM-derived metabolites exert beneficial effects against HCC by regulating multiple signaling pathways and targets, supporting their potential as therapeutic candidates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.